Discovering a better future
AeroNeph Therapeutics, Inc. has emerged from the humanized drug discovery approach of its parent company, DiscoveryBioMed, Inc., and is continuing to develop lead and hit-to-lead small molecules for specific human disease indications and for human taste marketplaces.
Who We AreR&D Programs
AeroNeph specializes in developing cell-based discovery assets. Through our various research and development programs, our goal is to improve the treatment for human genetic kidney and respiratory diseases, diabetes, obesity complications and lupus.
View Programs